nodes	percent_of_prediction	percent_of_DWPC	metapath
Chenodeoxycholic acid—primary biliary cirrhosis—systemic scleroderma	0.654	1	CtDrD
Chenodeoxycholic acid—UGT2B7—Mycophenolic acid—systemic scleroderma	0.139	0.602	CbGbCtD
Chenodeoxycholic acid—UGT2B7—Mycophenolate mofetil—systemic scleroderma	0.0776	0.336	CbGbCtD
Chenodeoxycholic acid—CYP3A4—Mycophenolate mofetil—systemic scleroderma	0.00797	0.0345	CbGbCtD
Chenodeoxycholic acid—CYP3A4—Prednisone—systemic scleroderma	0.00637	0.0276	CbGbCtD
Chenodeoxycholic acid—NR1H4—connective tissue—systemic scleroderma	0.000631	0.194	CbGeAlD
Chenodeoxycholic acid—CYP27A1—connective tissue—systemic scleroderma	0.000459	0.141	CbGeAlD
Chenodeoxycholic acid—NR1H4—digestive system—systemic scleroderma	0.000456	0.14	CbGeAlD
Chenodeoxycholic acid—CYP27A1—skin of body—systemic scleroderma	0.000415	0.127	CbGeAlD
Chenodeoxycholic acid—CYP27A1—digestive system—systemic scleroderma	0.000332	0.102	CbGeAlD
Chenodeoxycholic acid—CYP27A1—tendon—systemic scleroderma	0.000316	0.0969	CbGeAlD
Chenodeoxycholic acid—UGT2B7—digestive system—systemic scleroderma	0.000294	0.0901	CbGeAlD
Chenodeoxycholic acid—CYP27A1—lung—systemic scleroderma	0.000277	0.085	CbGeAlD
Chenodeoxycholic acid—CYP3A4—digestive system—systemic scleroderma	8.01e-05	0.0246	CbGeAlD
Chenodeoxycholic acid—Constipation—Mycophenolic acid—systemic scleroderma	5.58e-05	0.000497	CcSEcCtD
Chenodeoxycholic acid—Palpitations—Mycophenolate mofetil—systemic scleroderma	5.58e-05	0.000497	CcSEcCtD
Chenodeoxycholic acid—Weight decreased—Prednisone—systemic scleroderma	5.55e-05	0.000495	CcSEcCtD
Chenodeoxycholic acid—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	5.55e-05	0.000494	CcSEcCtD
Chenodeoxycholic acid—Cough—Mycophenolate mofetil—systemic scleroderma	5.51e-05	0.000491	CcSEcCtD
Chenodeoxycholic acid—Hypotension—Lisinopril—systemic scleroderma	5.49e-05	0.000489	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Captopril—systemic scleroderma	5.49e-05	0.000489	CcSEcCtD
Chenodeoxycholic acid—Liver function test abnormal—Methotrexate—systemic scleroderma	5.48e-05	0.000488	CcSEcCtD
Chenodeoxycholic acid—Convulsion—Mycophenolate mofetil—systemic scleroderma	5.47e-05	0.000487	CcSEcCtD
Chenodeoxycholic acid—Depression—Prednisone—systemic scleroderma	5.46e-05	0.000486	CcSEcCtD
Chenodeoxycholic acid—Hypertension—Mycophenolate mofetil—systemic scleroderma	5.45e-05	0.000485	CcSEcCtD
Chenodeoxycholic acid—Urticaria—Leflunomide—systemic scleroderma	5.43e-05	0.000484	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Leflunomide—systemic scleroderma	5.41e-05	0.000482	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Leflunomide—systemic scleroderma	5.41e-05	0.000482	CcSEcCtD
Chenodeoxycholic acid—Acute coronary syndrome—Prednisone—systemic scleroderma	5.4e-05	0.000481	CcSEcCtD
Chenodeoxycholic acid—Feeling abnormal—Mycophenolic acid—systemic scleroderma	5.38e-05	0.000479	CcSEcCtD
Chenodeoxycholic acid—Myalgia—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.000479	CcSEcCtD
Chenodeoxycholic acid—Arthralgia—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.000479	CcSEcCtD
Chenodeoxycholic acid—Chest pain—Mycophenolate mofetil—systemic scleroderma	5.37e-05	0.000479	CcSEcCtD
Chenodeoxycholic acid—Myocardial infarction—Prednisone—systemic scleroderma	5.37e-05	0.000478	CcSEcCtD
Chenodeoxycholic acid—Breast disorder—Methotrexate—systemic scleroderma	5.36e-05	0.000478	CcSEcCtD
Chenodeoxycholic acid—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	5.36e-05	0.000477	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Azathioprine—systemic scleroderma	5.34e-05	0.000476	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	5.34e-05	0.000475	CcSEcCtD
Chenodeoxycholic acid—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	5.34e-05	0.000475	CcSEcCtD
Chenodeoxycholic acid—Insomnia—Lisinopril—systemic scleroderma	5.32e-05	0.000474	CcSEcCtD
Chenodeoxycholic acid—Discomfort—Mycophenolate mofetil—systemic scleroderma	5.31e-05	0.000473	CcSEcCtD
Chenodeoxycholic acid—Paraesthesia—Lisinopril—systemic scleroderma	5.28e-05	0.00047	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Captopril—systemic scleroderma	5.28e-05	0.00047	CcSEcCtD
Chenodeoxycholic acid—Dry mouth—Mycophenolate mofetil—systemic scleroderma	5.25e-05	0.000468	CcSEcCtD
Chenodeoxycholic acid—Dyspnoea—Lisinopril—systemic scleroderma	5.24e-05	0.000467	CcSEcCtD
Chenodeoxycholic acid—Rash—Captopril—systemic scleroderma	5.23e-05	0.000466	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Captopril—systemic scleroderma	5.23e-05	0.000466	CcSEcCtD
Chenodeoxycholic acid—Somnolence—Lisinopril—systemic scleroderma	5.23e-05	0.000466	CcSEcCtD
Chenodeoxycholic acid—Headache—Captopril—systemic scleroderma	5.2e-05	0.000463	CcSEcCtD
Chenodeoxycholic acid—Confusional state—Mycophenolate mofetil—systemic scleroderma	5.19e-05	0.000463	CcSEcCtD
Chenodeoxycholic acid—Dyspepsia—Lisinopril—systemic scleroderma	5.17e-05	0.000461	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Mycophenolic acid—systemic scleroderma	5.16e-05	0.00046	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Mycophenolic acid—systemic scleroderma	5.16e-05	0.00046	CcSEcCtD
Chenodeoxycholic acid—Oedema—Mycophenolate mofetil—systemic scleroderma	5.15e-05	0.000459	CcSEcCtD
Chenodeoxycholic acid—Asthma—Methotrexate—systemic scleroderma	5.13e-05	0.000457	CcSEcCtD
Chenodeoxycholic acid—Infection—Mycophenolate mofetil—systemic scleroderma	5.12e-05	0.000456	CcSEcCtD
Chenodeoxycholic acid—Decreased appetite—Lisinopril—systemic scleroderma	5.11e-05	0.000455	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal disorder—Lisinopril—systemic scleroderma	5.07e-05	0.000452	CcSEcCtD
Chenodeoxycholic acid—Fatigue—Lisinopril—systemic scleroderma	5.07e-05	0.000452	CcSEcCtD
Chenodeoxycholic acid—Shock—Mycophenolate mofetil—systemic scleroderma	5.07e-05	0.000451	CcSEcCtD
Chenodeoxycholic acid—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	5.05e-05	0.00045	CcSEcCtD
Chenodeoxycholic acid—Thrombocytopenia—Mycophenolate mofetil—systemic scleroderma	5.04e-05	0.000449	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Leflunomide—systemic scleroderma	5.04e-05	0.000449	CcSEcCtD
Chenodeoxycholic acid—Pancreatitis—Methotrexate—systemic scleroderma	5.03e-05	0.000448	CcSEcCtD
Chenodeoxycholic acid—Pain—Lisinopril—systemic scleroderma	5.03e-05	0.000448	CcSEcCtD
Chenodeoxycholic acid—Constipation—Lisinopril—systemic scleroderma	5.03e-05	0.000448	CcSEcCtD
Chenodeoxycholic acid—Tachycardia—Mycophenolate mofetil—systemic scleroderma	5.03e-05	0.000448	CcSEcCtD
Chenodeoxycholic acid—Skin disorder—Mycophenolate mofetil—systemic scleroderma	5e-05	0.000446	CcSEcCtD
Chenodeoxycholic acid—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	4.98e-05	0.000444	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Azathioprine—systemic scleroderma	4.96e-05	0.000442	CcSEcCtD
Chenodeoxycholic acid—Haemoglobin—Prednisone—systemic scleroderma	4.94e-05	0.00044	CcSEcCtD
Chenodeoxycholic acid—Nausea—Captopril—systemic scleroderma	4.93e-05	0.000439	CcSEcCtD
Chenodeoxycholic acid—Abdominal discomfort—Methotrexate—systemic scleroderma	4.92e-05	0.000438	CcSEcCtD
Chenodeoxycholic acid—Haemorrhage—Prednisone—systemic scleroderma	4.91e-05	0.000438	CcSEcCtD
Chenodeoxycholic acid—Anorexia—Mycophenolate mofetil—systemic scleroderma	4.91e-05	0.000437	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Leflunomide—systemic scleroderma	4.91e-05	0.000437	CcSEcCtD
Chenodeoxycholic acid—Feeling abnormal—Lisinopril—systemic scleroderma	4.84e-05	0.000432	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Leflunomide—systemic scleroderma	4.84e-05	0.000431	CcSEcCtD
Chenodeoxycholic acid—Connective tissue disorder—Prednisone—systemic scleroderma	4.83e-05	0.00043	CcSEcCtD
Chenodeoxycholic acid—Hypotension—Mycophenolate mofetil—systemic scleroderma	4.81e-05	0.000429	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal pain—Lisinopril—systemic scleroderma	4.81e-05	0.000428	CcSEcCtD
Chenodeoxycholic acid—Dysuria—Methotrexate—systemic scleroderma	4.8e-05	0.000427	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Azathioprine—systemic scleroderma	4.79e-05	0.000427	CcSEcCtD
Chenodeoxycholic acid—Upper respiratory tract infection—Methotrexate—systemic scleroderma	4.77e-05	0.000425	CcSEcCtD
Chenodeoxycholic acid—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	4.69e-05	0.000418	CcSEcCtD
Chenodeoxycholic acid—Photosensitivity reaction—Methotrexate—systemic scleroderma	4.68e-05	0.000417	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Mycophenolic acid—systemic scleroderma	4.68e-05	0.000417	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Leflunomide—systemic scleroderma	4.68e-05	0.000417	CcSEcCtD
Chenodeoxycholic acid—Urticaria—Lisinopril—systemic scleroderma	4.67e-05	0.000416	CcSEcCtD
Chenodeoxycholic acid—Insomnia—Mycophenolate mofetil—systemic scleroderma	4.66e-05	0.000415	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Lisinopril—systemic scleroderma	4.65e-05	0.000414	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Lisinopril—systemic scleroderma	4.65e-05	0.000414	CcSEcCtD
Chenodeoxycholic acid—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	4.62e-05	0.000412	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Mycophenolic acid—systemic scleroderma	4.62e-05	0.000411	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Azathioprine—systemic scleroderma	4.61e-05	0.00041	CcSEcCtD
Chenodeoxycholic acid—Pneumonia—Methotrexate—systemic scleroderma	4.6e-05	0.00041	CcSEcCtD
Chenodeoxycholic acid—Eye disorder—Prednisone—systemic scleroderma	4.59e-05	0.000409	CcSEcCtD
Chenodeoxycholic acid—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	4.59e-05	0.000409	CcSEcCtD
Chenodeoxycholic acid—Somnolence—Mycophenolate mofetil—systemic scleroderma	4.58e-05	0.000408	CcSEcCtD
Chenodeoxycholic acid—Infestation NOS—Methotrexate—systemic scleroderma	4.57e-05	0.000408	CcSEcCtD
Chenodeoxycholic acid—Infestation—Methotrexate—systemic scleroderma	4.57e-05	0.000408	CcSEcCtD
Chenodeoxycholic acid—Rash—Azathioprine—systemic scleroderma	4.57e-05	0.000407	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Azathioprine—systemic scleroderma	4.56e-05	0.000407	CcSEcCtD
Chenodeoxycholic acid—Depression—Methotrexate—systemic scleroderma	4.56e-05	0.000406	CcSEcCtD
Chenodeoxycholic acid—Headache—Azathioprine—systemic scleroderma	4.54e-05	0.000404	CcSEcCtD
Chenodeoxycholic acid—Dyspepsia—Mycophenolate mofetil—systemic scleroderma	4.53e-05	0.000404	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Leflunomide—systemic scleroderma	4.52e-05	0.000403	CcSEcCtD
Chenodeoxycholic acid—Renal failure—Methotrexate—systemic scleroderma	4.5e-05	0.000401	CcSEcCtD
Chenodeoxycholic acid—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	4.48e-05	0.000399	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Mycophenolic acid—systemic scleroderma	4.47e-05	0.000398	CcSEcCtD
Chenodeoxycholic acid—Angiopathy—Prednisone—systemic scleroderma	4.46e-05	0.000397	CcSEcCtD
Chenodeoxycholic acid—Conjunctivitis—Methotrexate—systemic scleroderma	4.45e-05	0.000396	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	4.45e-05	0.000396	CcSEcCtD
Chenodeoxycholic acid—Immune system disorder—Prednisone—systemic scleroderma	4.44e-05	0.000395	CcSEcCtD
Chenodeoxycholic acid—Pain—Mycophenolate mofetil—systemic scleroderma	4.4e-05	0.000392	CcSEcCtD
Chenodeoxycholic acid—Constipation—Mycophenolate mofetil—systemic scleroderma	4.4e-05	0.000392	CcSEcCtD
Chenodeoxycholic acid—Arrhythmia—Prednisone—systemic scleroderma	4.39e-05	0.000391	CcSEcCtD
Chenodeoxycholic acid—Sweating—Methotrexate—systemic scleroderma	4.39e-05	0.000391	CcSEcCtD
Chenodeoxycholic acid—Haematuria—Methotrexate—systemic scleroderma	4.36e-05	0.000389	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Leflunomide—systemic scleroderma	4.35e-05	0.000388	CcSEcCtD
Chenodeoxycholic acid—Alopecia—Prednisone—systemic scleroderma	4.34e-05	0.000387	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Lisinopril—systemic scleroderma	4.33e-05	0.000386	CcSEcCtD
Chenodeoxycholic acid—Hepatobiliary disease—Methotrexate—systemic scleroderma	4.33e-05	0.000385	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Mycophenolic acid—systemic scleroderma	4.32e-05	0.000385	CcSEcCtD
Chenodeoxycholic acid—Epistaxis—Methotrexate—systemic scleroderma	4.31e-05	0.000384	CcSEcCtD
Chenodeoxycholic acid—Rash—Leflunomide—systemic scleroderma	4.31e-05	0.000384	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Leflunomide—systemic scleroderma	4.31e-05	0.000384	CcSEcCtD
Chenodeoxycholic acid—Nausea—Azathioprine—systemic scleroderma	4.3e-05	0.000383	CcSEcCtD
Chenodeoxycholic acid—Headache—Leflunomide—systemic scleroderma	4.29e-05	0.000382	CcSEcCtD
Chenodeoxycholic acid—Malnutrition—Prednisone—systemic scleroderma	4.28e-05	0.000381	CcSEcCtD
Chenodeoxycholic acid—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	4.24e-05	0.000378	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Lisinopril—systemic scleroderma	4.22e-05	0.000376	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	4.21e-05	0.000375	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Lisinopril—systemic scleroderma	4.16e-05	0.000371	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Mycophenolic acid—systemic scleroderma	4.15e-05	0.00037	CcSEcCtD
Chenodeoxycholic acid—Haemoglobin—Methotrexate—systemic scleroderma	4.13e-05	0.000368	CcSEcCtD
Chenodeoxycholic acid—Rash—Mycophenolic acid—systemic scleroderma	4.11e-05	0.000367	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Mycophenolic acid—systemic scleroderma	4.11e-05	0.000366	CcSEcCtD
Chenodeoxycholic acid—Haemorrhage—Methotrexate—systemic scleroderma	4.11e-05	0.000366	CcSEcCtD
Chenodeoxycholic acid—Urticaria—Mycophenolate mofetil—systemic scleroderma	4.09e-05	0.000365	CcSEcCtD
Chenodeoxycholic acid—Headache—Mycophenolic acid—systemic scleroderma	4.09e-05	0.000364	CcSEcCtD
Chenodeoxycholic acid—Pharyngitis—Methotrexate—systemic scleroderma	4.08e-05	0.000363	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	4.07e-05	0.000363	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	4.07e-05	0.000363	CcSEcCtD
Chenodeoxycholic acid—Nausea—Leflunomide—systemic scleroderma	4.06e-05	0.000362	CcSEcCtD
Chenodeoxycholic acid—Urinary tract disorder—Methotrexate—systemic scleroderma	4.06e-05	0.000361	CcSEcCtD
Chenodeoxycholic acid—Urethral disorder—Methotrexate—systemic scleroderma	4.03e-05	0.000359	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Lisinopril—systemic scleroderma	4.02e-05	0.000358	CcSEcCtD
Chenodeoxycholic acid—Ill-defined disorder—Prednisone—systemic scleroderma	3.97e-05	0.000354	CcSEcCtD
Chenodeoxycholic acid—Visual impairment—Methotrexate—systemic scleroderma	3.96e-05	0.000353	CcSEcCtD
Chenodeoxycholic acid—Anaemia—Prednisone—systemic scleroderma	3.95e-05	0.000352	CcSEcCtD
Chenodeoxycholic acid—Angioedema—Prednisone—systemic scleroderma	3.91e-05	0.000348	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Lisinopril—systemic scleroderma	3.89e-05	0.000346	CcSEcCtD
Chenodeoxycholic acid—Nausea—Mycophenolic acid—systemic scleroderma	3.88e-05	0.000345	CcSEcCtD
Chenodeoxycholic acid—Malaise—Prednisone—systemic scleroderma	3.86e-05	0.000344	CcSEcCtD
Chenodeoxycholic acid—Vertigo—Prednisone—systemic scleroderma	3.84e-05	0.000342	CcSEcCtD
Chenodeoxycholic acid—Eye disorder—Methotrexate—systemic scleroderma	3.84e-05	0.000342	CcSEcCtD
Chenodeoxycholic acid—Syncope—Prednisone—systemic scleroderma	3.84e-05	0.000342	CcSEcCtD
Chenodeoxycholic acid—Tinnitus—Methotrexate—systemic scleroderma	3.83e-05	0.000341	CcSEcCtD
Chenodeoxycholic acid—Cardiac disorder—Methotrexate—systemic scleroderma	3.81e-05	0.00034	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	3.79e-05	0.000338	CcSEcCtD
Chenodeoxycholic acid—Loss of consciousness—Prednisone—systemic scleroderma	3.76e-05	0.000335	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Lisinopril—systemic scleroderma	3.74e-05	0.000333	CcSEcCtD
Chenodeoxycholic acid—Angiopathy—Methotrexate—systemic scleroderma	3.73e-05	0.000332	CcSEcCtD
Chenodeoxycholic acid—Immune system disorder—Methotrexate—systemic scleroderma	3.71e-05	0.000331	CcSEcCtD
Chenodeoxycholic acid—Rash—Lisinopril—systemic scleroderma	3.71e-05	0.00033	CcSEcCtD
Chenodeoxycholic acid—Convulsion—Prednisone—systemic scleroderma	3.71e-05	0.00033	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Lisinopril—systemic scleroderma	3.7e-05	0.00033	CcSEcCtD
Chenodeoxycholic acid—Mediastinal disorder—Methotrexate—systemic scleroderma	3.7e-05	0.00033	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Mycophenolate mofetil—systemic scleroderma	3.7e-05	0.000329	CcSEcCtD
Chenodeoxycholic acid—Hypertension—Prednisone—systemic scleroderma	3.69e-05	0.000329	CcSEcCtD
Chenodeoxycholic acid—Chills—Methotrexate—systemic scleroderma	3.68e-05	0.000328	CcSEcCtD
Chenodeoxycholic acid—Headache—Lisinopril—systemic scleroderma	3.68e-05	0.000328	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Mycophenolate mofetil—systemic scleroderma	3.64e-05	0.000325	CcSEcCtD
Chenodeoxycholic acid—Arthralgia—Prednisone—systemic scleroderma	3.64e-05	0.000324	CcSEcCtD
Chenodeoxycholic acid—Myalgia—Prednisone—systemic scleroderma	3.64e-05	0.000324	CcSEcCtD
Chenodeoxycholic acid—Alopecia—Methotrexate—systemic scleroderma	3.63e-05	0.000323	CcSEcCtD
Chenodeoxycholic acid—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	3.62e-05	0.000322	CcSEcCtD
Chenodeoxycholic acid—Discomfort—Prednisone—systemic scleroderma	3.6e-05	0.000321	CcSEcCtD
Chenodeoxycholic acid—Malnutrition—Methotrexate—systemic scleroderma	3.58e-05	0.000319	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	3.52e-05	0.000314	CcSEcCtD
Chenodeoxycholic acid—Nausea—Lisinopril—systemic scleroderma	3.49e-05	0.000311	CcSEcCtD
Chenodeoxycholic acid—Oedema—Prednisone—systemic scleroderma	3.49e-05	0.000311	CcSEcCtD
Chenodeoxycholic acid—Infection—Prednisone—systemic scleroderma	3.47e-05	0.000309	CcSEcCtD
Chenodeoxycholic acid—Back pain—Methotrexate—systemic scleroderma	3.46e-05	0.000308	CcSEcCtD
Chenodeoxycholic acid—Shock—Prednisone—systemic scleroderma	3.43e-05	0.000306	CcSEcCtD
Chenodeoxycholic acid—Nervous system disorder—Prednisone—systemic scleroderma	3.42e-05	0.000305	CcSEcCtD
Chenodeoxycholic acid—Tachycardia—Prednisone—systemic scleroderma	3.41e-05	0.000304	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Mycophenolate mofetil—systemic scleroderma	3.41e-05	0.000303	CcSEcCtD
Chenodeoxycholic acid—Skin disorder—Prednisone—systemic scleroderma	3.39e-05	0.000302	CcSEcCtD
Chenodeoxycholic acid—Hyperhidrosis—Prednisone—systemic scleroderma	3.38e-05	0.000301	CcSEcCtD
Chenodeoxycholic acid—Anorexia—Prednisone—systemic scleroderma	3.33e-05	0.000297	CcSEcCtD
Chenodeoxycholic acid—Ill-defined disorder—Methotrexate—systemic scleroderma	3.32e-05	0.000296	CcSEcCtD
Chenodeoxycholic acid—Anaemia—Methotrexate—systemic scleroderma	3.3e-05	0.000294	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Mycophenolate mofetil—systemic scleroderma	3.27e-05	0.000292	CcSEcCtD
Chenodeoxycholic acid—Rash—Mycophenolate mofetil—systemic scleroderma	3.25e-05	0.000289	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Mycophenolate mofetil—systemic scleroderma	3.24e-05	0.000289	CcSEcCtD
Chenodeoxycholic acid—Headache—Mycophenolate mofetil—systemic scleroderma	3.23e-05	0.000287	CcSEcCtD
Chenodeoxycholic acid—Malaise—Methotrexate—systemic scleroderma	3.22e-05	0.000287	CcSEcCtD
Chenodeoxycholic acid—Vertigo—Methotrexate—systemic scleroderma	3.21e-05	0.000286	CcSEcCtD
Chenodeoxycholic acid—Leukopenia—Methotrexate—systemic scleroderma	3.2e-05	0.000285	CcSEcCtD
Chenodeoxycholic acid—Musculoskeletal discomfort—Prednisone—systemic scleroderma	3.18e-05	0.000283	CcSEcCtD
Chenodeoxycholic acid—Insomnia—Prednisone—systemic scleroderma	3.16e-05	0.000281	CcSEcCtD
Chenodeoxycholic acid—Paraesthesia—Prednisone—systemic scleroderma	3.13e-05	0.000279	CcSEcCtD
Chenodeoxycholic acid—Cough—Methotrexate—systemic scleroderma	3.12e-05	0.000278	CcSEcCtD
Chenodeoxycholic acid—Convulsion—Methotrexate—systemic scleroderma	3.1e-05	0.000276	CcSEcCtD
Chenodeoxycholic acid—Dyspepsia—Prednisone—systemic scleroderma	3.07e-05	0.000274	CcSEcCtD
Chenodeoxycholic acid—Nausea—Mycophenolate mofetil—systemic scleroderma	3.06e-05	0.000273	CcSEcCtD
Chenodeoxycholic acid—Myalgia—Methotrexate—systemic scleroderma	3.04e-05	0.000271	CcSEcCtD
Chenodeoxycholic acid—Chest pain—Methotrexate—systemic scleroderma	3.04e-05	0.000271	CcSEcCtD
Chenodeoxycholic acid—Arthralgia—Methotrexate—systemic scleroderma	3.04e-05	0.000271	CcSEcCtD
Chenodeoxycholic acid—Decreased appetite—Prednisone—systemic scleroderma	3.03e-05	0.00027	CcSEcCtD
Chenodeoxycholic acid—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	3.02e-05	0.000269	CcSEcCtD
Chenodeoxycholic acid—Fatigue—Prednisone—systemic scleroderma	3.01e-05	0.000268	CcSEcCtD
Chenodeoxycholic acid—Discomfort—Methotrexate—systemic scleroderma	3.01e-05	0.000268	CcSEcCtD
Chenodeoxycholic acid—Constipation—Prednisone—systemic scleroderma	2.99e-05	0.000266	CcSEcCtD
Chenodeoxycholic acid—Confusional state—Methotrexate—systemic scleroderma	2.94e-05	0.000262	CcSEcCtD
Chenodeoxycholic acid—Infection—Methotrexate—systemic scleroderma	2.9e-05	0.000258	CcSEcCtD
Chenodeoxycholic acid—Feeling abnormal—Prednisone—systemic scleroderma	2.88e-05	0.000256	CcSEcCtD
Chenodeoxycholic acid—Nervous system disorder—Methotrexate—systemic scleroderma	2.86e-05	0.000255	CcSEcCtD
Chenodeoxycholic acid—Thrombocytopenia—Methotrexate—systemic scleroderma	2.86e-05	0.000255	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal pain—Prednisone—systemic scleroderma	2.85e-05	0.000254	CcSEcCtD
Chenodeoxycholic acid—Skin disorder—Methotrexate—systemic scleroderma	2.83e-05	0.000253	CcSEcCtD
Chenodeoxycholic acid—Hyperhidrosis—Methotrexate—systemic scleroderma	2.82e-05	0.000251	CcSEcCtD
Chenodeoxycholic acid—Anorexia—Methotrexate—systemic scleroderma	2.78e-05	0.000248	CcSEcCtD
Chenodeoxycholic acid—Urticaria—Prednisone—systemic scleroderma	2.77e-05	0.000247	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Prednisone—systemic scleroderma	2.76e-05	0.000246	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Prednisone—systemic scleroderma	2.76e-05	0.000246	CcSEcCtD
Chenodeoxycholic acid—Hypotension—Methotrexate—systemic scleroderma	2.73e-05	0.000243	CcSEcCtD
Chenodeoxycholic acid—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	2.66e-05	0.000237	CcSEcCtD
Chenodeoxycholic acid—Insomnia—Methotrexate—systemic scleroderma	2.64e-05	0.000235	CcSEcCtD
Chenodeoxycholic acid—Paraesthesia—Methotrexate—systemic scleroderma	2.62e-05	0.000233	CcSEcCtD
Chenodeoxycholic acid—Dyspnoea—Methotrexate—systemic scleroderma	2.6e-05	0.000232	CcSEcCtD
Chenodeoxycholic acid—Somnolence—Methotrexate—systemic scleroderma	2.59e-05	0.000231	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Prednisone—systemic scleroderma	2.57e-05	0.000229	CcSEcCtD
Chenodeoxycholic acid—Dyspepsia—Methotrexate—systemic scleroderma	2.57e-05	0.000229	CcSEcCtD
Chenodeoxycholic acid—Decreased appetite—Methotrexate—systemic scleroderma	2.54e-05	0.000226	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal disorder—Methotrexate—systemic scleroderma	2.52e-05	0.000224	CcSEcCtD
Chenodeoxycholic acid—Fatigue—Methotrexate—systemic scleroderma	2.52e-05	0.000224	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Prednisone—systemic scleroderma	2.5e-05	0.000223	CcSEcCtD
Chenodeoxycholic acid—Pain—Methotrexate—systemic scleroderma	2.5e-05	0.000222	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Prednisone—systemic scleroderma	2.47e-05	0.00022	CcSEcCtD
Chenodeoxycholic acid—Feeling abnormal—Methotrexate—systemic scleroderma	2.4e-05	0.000214	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Prednisone—systemic scleroderma	2.39e-05	0.000213	CcSEcCtD
Chenodeoxycholic acid—Gastrointestinal pain—Methotrexate—systemic scleroderma	2.39e-05	0.000213	CcSEcCtD
Chenodeoxycholic acid—Urticaria—Methotrexate—systemic scleroderma	2.32e-05	0.000207	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Prednisone—systemic scleroderma	2.31e-05	0.000206	CcSEcCtD
Chenodeoxycholic acid—Body temperature increased—Methotrexate—systemic scleroderma	2.31e-05	0.000206	CcSEcCtD
Chenodeoxycholic acid—Abdominal pain—Methotrexate—systemic scleroderma	2.31e-05	0.000206	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Prednisone—systemic scleroderma	2.22e-05	0.000198	CcSEcCtD
Chenodeoxycholic acid—Rash—Prednisone—systemic scleroderma	2.2e-05	0.000196	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Prednisone—systemic scleroderma	2.2e-05	0.000196	CcSEcCtD
Chenodeoxycholic acid—Headache—Prednisone—systemic scleroderma	2.19e-05	0.000195	CcSEcCtD
Chenodeoxycholic acid—Hypersensitivity—Methotrexate—systemic scleroderma	2.15e-05	0.000192	CcSEcCtD
Chenodeoxycholic acid—Asthenia—Methotrexate—systemic scleroderma	2.09e-05	0.000187	CcSEcCtD
Chenodeoxycholic acid—Nausea—Prednisone—systemic scleroderma	2.07e-05	0.000185	CcSEcCtD
Chenodeoxycholic acid—Pruritus—Methotrexate—systemic scleroderma	2.06e-05	0.000184	CcSEcCtD
Chenodeoxycholic acid—Diarrhoea—Methotrexate—systemic scleroderma	2e-05	0.000178	CcSEcCtD
Chenodeoxycholic acid—Dizziness—Methotrexate—systemic scleroderma	1.93e-05	0.000172	CcSEcCtD
Chenodeoxycholic acid—Vomiting—Methotrexate—systemic scleroderma	1.86e-05	0.000165	CcSEcCtD
Chenodeoxycholic acid—Rash—Methotrexate—systemic scleroderma	1.84e-05	0.000164	CcSEcCtD
Chenodeoxycholic acid—Dermatitis—Methotrexate—systemic scleroderma	1.84e-05	0.000164	CcSEcCtD
Chenodeoxycholic acid—Headache—Methotrexate—systemic scleroderma	1.83e-05	0.000163	CcSEcCtD
Chenodeoxycholic acid—Nausea—Methotrexate—systemic scleroderma	1.73e-05	0.000154	CcSEcCtD
